TY - CHAP M1 - Book, Section TI - Renal Cell Carcinoma A1 - Dall’Era, Marc A. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2023 N1 - T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Renal Cell CarcinomaFor patients with von Hippel-Lindau disease and renal cell carcinoma, belzutifan, a HIF2a inhibitor, leads to dramatic size reductions in both renal and non-renal neoplasms and offers a new treatment option.Pembrolizumab is FDA-approved for adjuvant treatment after surgical resection of renal cell carcinoma in patients at high risk for disease recurrence.The SURTIME randomized trial compared immediate versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with sunitinib and showed an overall survival advantage with the deferred approach. This may serve to identify patients who respond the best to systemic therapy prior to undergoing removal of the primary tumor.Bex A et al. JAMA Oncol. [PMID: 30543350]Jonasch E et al. N Engl J Med. [PMID: 34818478]Rini BI et al; KEYNOTE-426 Investigators. N Engl J Med. [PMID: 30779529] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193162674 ER -